What is SXTP's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.00B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for SXTP?

P/E (TTM) is n/a and 52-week range is $0.59 to $8.62 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s SXTP figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for SXTP?

The company profile lists revenue (TTM) near $2M, net income (TTM) near -$1.08B, EPS (TTM) near -$5.93 when available from the market-data feed. Figures are informational and may lag live markets.

Where is 60 Degrees Pharmaceuticals Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Washington, Washington Dc, US, 3.5M shares outstanding, ISIN US83006G5009 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

60 Degrees Pharmaceuticals Inc

$SXTP

Health Care · Pharmaceuticals

IR Run Scenarios

Overview Charts AI Summary Financials Valuation

Profile

Read AI summary

60 Degrees Pharmaceuticals, Inc. develops medicines for the treatment and prevention of infectious diseases. The company is headquartered in Washington, Washington Dc and currently employs 3 full-time employees. The company went IPO on 2023-07-12. The firm specializes in developing and marketing new medicines for the treatment and prevention of infectious diseases. The company is focused on using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. The firm's pipeline under development covers development programs for vector-borne, fungal, and viral disease utilizing three of the Company’s products: new products that contain the ARAKODA regimen of Tafenoquine; new products that contain Tafenoquine, and Celgosivir. Its lead product, ARAKODA is used for malaria prevention in individuals 18 years and older. The company is also conducting due diligence activities in relation to potential in-licensing of a product relevant to Lyme disease and an antimalarial combination partner for Tafenoquine for P. vivax malaria.

Employees

Website

60degreespharma.com/

IPO

2023-07-12

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)

EPS (TTM)

P/E (price / listing EPS)

P/S (TTM)

Forward P/E

Forward P/S

EV / EBITDA

PEG (TTM)

FCF yield (TTM)

Gross margin (TTM)

Net margin (TTM)

Forward revenue growth (NTM)

Dividend / share (TTM)

Dividend yield (TTM)

Payout ratio (TTM)

Dividend growth (5Y)

Company context

Exchange

NASDAQ NMS - GLOBAL MARKET

ISIN

US83006G5009

Headquarters

Washington, Washington Dc, US

Shares outstanding

3.5M

NAICS sector

Manufacturing

Institutional ownership

16.56%

Browse other companiesFree AI scores and summaries for more stocks